18,077 followers
Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report: MET exon 14 skipping mutation (METex14m) is rare and occurs in approximately 1-4% of all #oncology… https://t.co/54x